Vor Bio secures $4bn deal with RemeGen for autoimmune drug, stock surged 45%.

From Yahoo Finance: 2025-06-26 12:49:00

Vor Bio, previously on the brink, secures a licensing deal with RemeGen for autoimmune drug telitacicept. The deal could reach $4bn, with an initial payment of $125m. Shares in Vor Bio surged by 45% following the announcement. RemeGen retains rights in certain regions. Telitacicept is already approved in China for several autoimmune conditions.

RemeGen is conducting a global Phase III trial for telitacicept in the treatment of myasthenia gravis. Initial results are expected in the first half of 2027. Vor Bio, once focused on cell and gene therapy, shifted to autoimmune treatment. The company’s new CEO, Dr. Jean-Paul Kress, aims to establish Vor Bio as a key player in autoimmune disease treatment.

The deal highlights Vor Bio’s transition to autoimmune therapies. The market for autoimmune drugs is lucrative, with drugs like Dupixent generating high sales. Analysts predict the rheumatoid arthritis drug market to reach $29.1bn by 2029. Dr. Kress, former CEO of MorphoSys, will lead Vor Bio in advancing innovative therapies for autoimmune diseases.



Read more at Yahoo Finance: Vor Bio back from brink with autoimmune drug deal rising to $4bn